SCHEMBL4388408

SCHEMBL4388408

Nc1ccccc1NC(=O)c1ccc(C(CCCN2CCOCC2)NC(=O)Nc2ccc3c(c2)OCO3)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.54
NPC1 O15118 3/20 0.51
LMNA P02545 2/20 0.51
TP53 P04637 2/20 0.51
MAPK1 P28482 2/20 0.51
USP2 O75604 1/20 0.51
EPHX2 P34913 2/20 0.50
RAB9A P51151 3/20 0.45
POLB P06746 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HDAC3 O15379 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2478586 0.91 HDAC1 (0.60) HDAC1NPC1LMNATP53MAPK1
SCHEMBL2476882 0.88 HDAC3 (0.51) HDAC1EPHX2POLBHDAC3HDAC2
SCHEMBL2477336 0.87 HDAC1 (0.56) HDAC1NPC1LMNATP53RAB9A
SCHEMBL2473466 0.87 HDAC1 (0.61) HDAC1LMNAEPHX2ALDH1A1HDAC3
SCHEMBL2473928 0.86 HDAC1 (0.47) HDAC1EPHX2POLBHDAC3HDAC2
SCHEMBL2474349 0.86 EGFR (0.49) HDAC1NPC1MAPK1EPHX2RAB9A
SCHEMBL2473979 0.86 HDAC1 (0.47) HDAC1NPC1LMNAMAPK1EPHX2
SCHEMBL4392742 0.86 HDAC1 (0.56) HDAC1LMNAUSP2EPHX2ALDH1A1
SCHEMBL2478730 0.85 HDAC1 (0.49) HDAC1MAPK1EPHX2POLBALDH1A1
SCHEMBL2473990 0.85 HDAC1 (0.67) HDAC1NPC1TP53RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885NPC1 989/4885LMNA 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.